All In Biotech

Drug Trial Radar · NCT03906071

Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 577 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

577

Actual

Start

Jul 15, 2019

Primary completion

Mar 20, 2023

Study completion Sep 30, 2025

Sponsor

Lead sponsor
Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
Bristol-Myers Squibb
First posted
Apr 8, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or after platinum-based chemotherapy and checkpoint inhibitor therapy.

Conditions

  • Metastatic Non-Squamous Non-Small Cell Lung Cancer

Interventions

  • NivolumabBiological

    Nivolumab is an antibody directed at the programmed death receptor-1 (PD-1), blocking its interaction with PD-L1 and PD-L2.

  • SitravatinibDrug

    Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.

  • DocetaxelDrug

    Docetaxel is an anti-neoplastic agent that acts by disrupting the microtubular network in cells.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From randomization date to date of death due to any cause (Up to approximately 44 months)

Locations

261 sites in 12 countries. Site status is shown where the registry gives one.

  • Local Institution - 005-164

    Birmingham, Alabama

  • Clearview Cancer Institute - Huntsville

    Huntsville, Alabama

  • Palo Verde Cancer Specialists - Glendale

    Glendale, Arizona

  • The Oncology Institute of Hope & Innovation - Tucson

    Tucson, Arizona

  • Yuma Regional Medical Center

    Yuma, Arizona

  • Local Institution - 005-174

    Jonesboro, Arkansas

  • NEA Baptist Fowler Family Center for Cancer Care

    Jonesboro, Arkansas

  • Highlands Oncology Group - Springdale

    Springdale, Arkansas

  • Comprehensive Blood and Cancer Center - Bakersfield

    Bakersfield, California

  • Local Institution - 005-118

    Beverly Hills, California

  • Local Institution - 005-171

    Fresno, California

  • Providence Medical Foundation - Virginia K. Crosson Cancer Center - Fullerton

    Fullerton, California

  • Local Institution - 005-096

    Long Beach, California

  • Cancer and Blood Specialty Clinic

    Los Alamitos, California

  • Los Angeles Hematology Oncology Medical Group

    Los Angeles, California

  • Local Institution - 005-185

    Los Angeles, California

  • Local Institution - 005-072

    Newport Beach, California

  • Local Institution - 005-109

    Northridge, California

  • Local Institution - 005-177

    Redlands, California

  • Local Institution - 005-112

    Riverside, California

  • University of California San Francisco

    San Francisco, California

  • Local Institution - 005-176

    San Marcos, California

  • Local Institution - 005-192

    Torrance, California

  • Local Institution - 005-090

    West Covina, California

  • Local Institution - 005-105

    Whittier, California

  • Local Institution - 005-097

    Lafayette, Colorado

  • Eastern Connecticut Hematology and Oncology Associates

    Norwich, Connecticut

  • Michael and Dianne Bienes Comprehensive Cancer Center

    Fort Lauderdale, Florida

  • Local Institution - 005-120

    Fort Myers, Florida

  • Memorial Regional Hospital

    Hollywood, Florida

  • Watson Clinic Cancer and Research Center

    Lakeland, Florida

  • Mount Sinai Health System

    Miami Beach, Florida

  • Local Institution - 005-120E

    Naples, Florida

  • Local Institution - 005-079

    Ocala, Florida

  • Local Institution - 005-104

    Orlando, Florida

  • SCRI - Florida Cancer Specialists - North Region Research Office

    St. Petersburg, Florida

  • SCRI - Florida Cancer Specialists - Panhandle Research Office

    Tallahassee, Florida

  • Local Institution - 005-154

    West Palm Beach, Florida

  • University Cancer & Blood Center (UCBC) - Athens

    Athens, Georgia

  • Local Institution - 005-146

    Atlanta, Georgia

Showing 40 of 261 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.